Narrative review evaluates blood-based biomarkers assessing symptom burden and quality of life in older cancer patients, suggesting promising tools for management.
Background: To evaluate the clinical utility of blood-based inflammatory and metabolic biomarkers in assessing symptom burden and quality of life among older adults with cancer. Methods: This review synthesizes current evidence regarding the clinical utility and underlying pathophysiological mechanisms of blood-based biomarkers, focusing particularly on the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and modified Glasgow prognostic score (mGPS). Results: Elevated inflammatory markers, such as NLR and SII, independently correlate with increased frailty and functional decline. Concurrently, nutritional-metabolic markers, including hypoalbuminemia and a high mGPS, are strongly associated with anorexia and cancer cachexia. These composite indicators effectively capture the synergistic effects of “inflammaging”, neuroinflammation, and tumor-driven metabolic reprogramming. Conclusion: Objective, cost-effective, and dynamically measurable inflammatory and metabolic biomarkers represent promising adjunctive tools for early symptom screening. The integration of these markers into comprehensive geriatric assessments may enhance risk stratification and symptom management. However, current evidence is constrained by study heterogeneity, retrospective designs, a lack of standardized cutoffs, and insufficient prospective validation in older cancer populations. Therefore, these biomarkers should be regarded as complementary to traditional assessments rather than definitive standalone tools. Infographic on blood biomarkers for symptom burden and life quality in aging and cancer patients.The infographic highlights blood-based biomarkers for evaluating symptom burden and quality of life in aging and cancer patients. Aging leads to inflammaging, while cancer causes metabolic reprogramming, both increasing inflammation (NLR, SII) and altering metabolism (mGPS, AST/ALT, LDH). These changes impact the brain/CNS with fatigue and cognitive decline and muscles with cachexia and sarcopenia. A three-tier risk model is used: Tier 1 (Low-Risk) for routine follow-up, Tier 2 (Intermediate-Risk) for personalized adjustments and Tier 3 (High-Risk) for proactive monitoring. Optimized symptom tracking and tailored treatments are advised. The clinical takeaway suggests promising adjunctive tools, a hypothesis-generating framework and future needs for clinical implementation and validation.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: